Home > Boards > US Listed > Biotechs > Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics price target lowered to $7 from

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
realfast95 Member Profile
Member Level 
Followed By 53
Posts 15,576
Boards Moderated 0
Alias Born 11/29/06
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/21/2021 4:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/21/2021 8:41:01 AM
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film fo... PR Newswire (US) - 1/21/2021 8:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/20/2021 6:05:35 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 1/8/2021 4:46:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/8/2021 7:01:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2021 7:36:05 AM
Aquestive Therapeutics Provides Business Update GlobeNewswire Inc. - 1/7/2021 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 4:06:10 PM
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 1/4/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 7:00:55 AM
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer GlobeNewswire Inc. - 12/16/2020 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 12/1/2020 6:01:05 AM
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/25/2020 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2020 7:15:57 AM
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization GlobeNewswire Inc. - 11/23/2020 7:00:00 AM
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant GlobeNewswire Inc. - 11/18/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2020 4:36:10 PM
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/4/2020 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2020 7:03:47 AM
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million GlobeNewswire Inc. - 11/3/2020 7:00:00 AM
Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conf... GlobeNewswire Inc. - 10/14/2020 7:30:10 AM
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of S... GlobeNewswire Inc. - 9/25/2020 5:38:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 5:28:37 PM
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic ... GlobeNewswire Inc. - 8/20/2020 7:30:10 AM
realfast95 Member Level  Monday, 09/28/20 12:00:45 PM
Re: None
Post # of 143 
Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street

Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »

Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.

Read more at:
https://thefly.com/n.php?id=3166457
Aquestive Therapeutics price target lowered to $17 from $23 at JMP

Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.

Read more at:
https://thefly.com/n.php?id=3166393Securities »

https://thefly.com/news.php?symbol=AQST

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences